大うつ病性障害：グローバル企業動向...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 13
3 Market Outlook 14
3.1 Global 14
3.1.1 Forecast 14
3.1.2 Drivers and Barriers – Global Issues 18
4 Current and Future Players 20
4.1 Overview 20
4.2 Trends in Corporate Strategy 23
4.3 Company Profiles 24
4.3.1 Lundbeck 24
4.3.2 Forest Laboratories (Actavis) 28
4.3.3 Eli Lilly 31
4.3.4 Pfizer 32
4.3.5 Otsuka Pharmaceutical 34
4.3.6 AstraZeneca 37
4.3.7 Takeda Pharmaceutical 38
4.3.8 Alkermes 40
4.3.9 Euthymics Bioscience 42
4.3.10 Naurex 44
4.3.11 e-Therapeutics 46
5 Appendix 49
5.1 Bibliography 49
5.2 Abbreviations 50
5.3 Methodology 52
5.4 Forecasting Methodology 52
5.4.1 Diagnosed MDD Patients 52
5.4.2 Percent of Drug-Treated Patients 52
5.4.3 General Pricing Assumptions 53
5.4.4 Generic Erosion 54
5.5 Physicians and Specialists Included in this Study 54
5.6 About the Authors 56
5.6.1 Analyst 56
5.6.2 Therapy Area Directors 56
5.6.3 Global Head of Healthcare 57
5.7 About GlobalData 58
5.8 Disclaimer 58